DEA Advances Psilocybin Rescheduling, Psylutions Ready for Medical Breakthrough

Psylutions, Colorado's first licensed regulated cultivator and manufacturer of psilocybin, has welcomed the U.S. Drug Enforcement Administration's landmark decision to forward a petition to reschedule psilocybin to the U.S. Department of Health and Human Services for scientific review. This regulatory milestone represents a significant shift in the decades-long effort to integrate psychedelics into mainstream medicine, with company founder Rhonda DeSantis praising the move as "a long-overdue alignment between policy and science." The company, which has invested heavily in infrastructure including strain optimization, lab-verified dosing, and triple HEPA filtration systems, stands ready to support this transition with their precision-grown, lab-verified psychedelic therapies.

If psilocybin is successfully moved from Schedule I to Schedule II of the Controlled Substances Act, patients in palliative care and Veterans suffering from PTSD would be among the first to benefit through expanded pathways like Right to Try. Henry Baskerville, General Counsel and Partner at Psylutions, described this development as signaling "a regulatory awakening" and "a watershed moment for psychedelics," noting that psychedelics hold even greater potential for significant medical applications than cannabis. Psylutions already partners with over 50% of healing centers operating across Colorado to provide regulated psilocybin solutions for chronic pain, trauma relief, end-of-life care, and broader mental wellness, positioning them at the forefront of this emerging medical frontier.

The company emphasizes its commitment to making psilocybin access built on medicine that is effective, rigorously verified, and responsibly produced. As DeSantis highlighted, "As soon as psilocybin is rescheduled from Schedule I, patients facing terminal illness and Veterans at risk of suicide will finally have safe, legal access through Right to Try." This development accelerates research opportunities and expands access for clinicians and licensed healing centers, with Psylutions setting a new standard for safety, purity, and purpose in the regulated psychedelics industry through their growing portfolio of high-potency strains and scientific excellence.